Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 270 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Herpes Simplex Virus Infection Clear all
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

NCT05432583
View directory record Official record
Conditions
Genital Herpes Simplex Type 2
Interventions
BNT163, Placebo
Biological · Other
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years to 55 Years
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
6
States / cities
Tempe, Arizona • Chicago, Illinois • Raleigh, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 2 Interventional

A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes

NCT00486200
View directory record Official record
Conditions
Herpes Genitalis
Interventions
ASP2151, valacyclovir, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
25
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2017 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Not applicable Interventional

A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients

NCT00002084
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Valacyclovir hydrochloride, Acyclovir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
46
States / cities
Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis

NCT00453401
View directory record Official record
Conditions
Herpes Labialis
Interventions
NB-001
Drug
Lead sponsor
NanoBio Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
28
States / cities
Huntsville, Alabama • Anaheim, California • Westlake Village, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 30, 2008 · Synced Oct 9, 2026, 4:13 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults

NCT05703607
View directory record Official record
Conditions
Shingles, Herpes Zoster Infection, Human
Interventions
Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection, Candidate 3: PF-07921186: VZV modRNA Suspension for Injection, Shingrix, Candidate 2: PF-07921188: VZV modRNA Powder for Suspension for Injection
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
484 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
35
States / cities
Gilbert, Arizona • Mesa, Arizona • Palo Alto, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Results available

Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes

NCT02871492
View directory record Official record
Conditions
Herpes Labialis
Interventions
Pritelivir 5% w/w ointment, Pritelivir ointment matching placebo, Zovirax® cream
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Scottsdale, Arizona • Santa Rosa, California • Pinellas Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

VivaGel™ in Healthy Young Women

NCT00331032
View directory record Official record
Conditions
Herpes Simplex II
Interventions
3% w/w SPL7013 Gel, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 24 Years · Female only
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2013 · Synced Oct 9, 2026, 4:13 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Viral Infections in Healthy and Immunocompromised Hosts

NCT01306084
View directory record Official record
Conditions
Anogenital Herpes, COVID-19, Herpes Labialis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 1 Interventional

Trial Evaluating Safety, Tolerability and Immune Response of AG-707

NCT00231049
View directory record Official record
Conditions
Genital Herpes
Interventions
AG-707
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
3
States / cities
Indianapolis, Indiana • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 27, 2008 · Synced Oct 9, 2026, 4:13 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

300 Antibody Diagnostic Test Kit

NCT01646411
View directory record Official record
Conditions
Acute Bacterial Infections, Acute Viral Infections
Interventions
Not listed
Lead sponsor
The Plasma Source
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Southampton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 20, 2012 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 3 Interventional

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects

NCT03073967
View directory record Official record
Conditions
HSV Infection
Interventions
Pritelivir, Investigator's choice
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
16 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
33
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study of Switching From One Pain Medication to Another (Opioid Rotation)

NCT00580294
View directory record Official record
Conditions
Pain
Interventions
Oxymorphone
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Oct 9, 2026, 4:13 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants

NCT05831111
View directory record Official record
Conditions
Epstein-Barr Virus Infection
Interventions
mRNA-1195.1, mRNA-1195.2, mRNA-1189, Placebo, mRNA-1195
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
482 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
34
States / cities
Anniston, Alabama • Tucson, Arizona • Huntington Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

Zinc for the Treatment of Herpes Simplex Labialis (HSL)

NCT00809809
View directory record Official record
Conditions
Herpes Simplex Labialis
Interventions
Zicam (Ionic zinc), placebo
Drug
Lead sponsor
Integrative Medicine Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Tempe, Arizona • Santa Fe, New Mexico • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Oct 9, 2026, 4:13 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population

NCT05580458
View directory record Official record
Conditions
Herpes Zoster
Interventions
Shingrix
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Not applicable Interventional

SP-303T Applied to the Skin of Patients With Herpes Simplex Virus (HSV) Infection and AIDS Who Have Not Had Success With Acyclovir

NCT00002310
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Crofelemer
Drug
Lead sponsor
Shaman Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
San Francisco, California • Fort Lauderdale, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Valacyclovir+Temovate Gel for the Treatment of Herpes Labialis

NCT00297011
View directory record Official record
Conditions
Herpes Labialis
Interventions
valacyclovir+clobetasol gel
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 6, 2008 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers

NCT01767467
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes zoster vaccine (GSK 1437173A), Placebo
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
568 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
8
States / cities
Inverness, Florida • Chicago, Illinois • Elkhart, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 9, 2026, 4:13 PM EDT
Withdrawn Phase 2 Interventional

HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma

NCT04482933
View directory record Official record
Conditions
Neoplasms, High Grade Glioma, Glioblastoma Multiforme, Malignant Glioma of Brain, Anaplastic Astrocytoma of Brain, High-grade Glioma, Anaplastic Glioma, Giant Cell Glioblastoma
Interventions
Biological G207
Biological
Lead sponsor
Pediatric Brain Tumor Consortium
Network
Eligibility
3 Years to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
5
States / cities
Aurora, Colorado • New York, New York • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 9, 2026, 4:13 PM EDT
Not listed Phase 3 Interventional

Phase III Randomized Study of Oral Acyclovir in Infants With Herpes Simplex Virus Infection Involving the Central Nervous System

NCT00006132
View directory record Official record
Conditions
Herpes Simplex
Interventions
acyclovir
Drug
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years to 28 Days
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
26
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older

NCT01954251
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster vaccine GSK 1437173A, GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
829 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
3
States / cities
Phoenix, Arizona • Carnegie, Pennsylvania • Erie, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 2 Interventional

Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients

NCT00000953
View directory record Official record
Conditions
HIV Infections, Chickenpox
Interventions
Sorivudine, Acyclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Birmingham, Alabama • Los Angeles, California • Martinez, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Pharmacokinetics of Famciclovir Single 1500 mg Dose in Adolescents With Recurrent Herpes Labialis

NCT00878072
View directory record Official record
Conditions
Herpes Labialis
Interventions
Famciclovir
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 18 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
12
States / cities
San Diego, California • Chicago, Illinois • Evansville, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 9, 2026, 4:13 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

NCT01165177
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
16,165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
43
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 9, 2026, 4:13 PM EDT